SKYE · Skye Bioscience Inc
United States · RS rating 81 · As of 2026-10-14
| Price | 1.57 USD |
|---|---|
| 1-day change | +2.6% |
| RS rating (overall / 1M / 3M / 12M) | 81 / 8 / 98 / 53 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 27 / 47 / 30 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -12.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +29.6% |
| Market cap (USD) | $31.6M |